Identification of MiRNAs in Cervical Mucus As a Novel Diagnostic Marker for Cervical Neoplasia

Overview

Journal Sci Rep

Specialty Science

Date 2018 May 6

PMID 29728572

Citations 25

Authors

Satoshi Kawai

Takuma Fujii

Iwao Kukimoto

Hiroya Yamada

Naoki Yamamoto

Makoto Kuroda

Sayaka Otani

Ryoko Ichikawa

Eiji Nishio

Yutaka Torii

Aya Iwata

Affiliations

Soon will be listed here.

Abstract

microRNAs (miRNAs) play important roles in regulation of gene expression during cervical carcinogenesis. We investigated expression profiles of miRNAs in cervical cancer and its precursor lesions by utilizing cervical mucus. Cervical mucus was collected from 230 patients with a normal cervix, cervical intraepithelial neoplasia (CIN), squamous cell carcinoma (SCC), or adenocarcinoma (AD). The levels of miRNA in the mucus were quantified by miRNA array and real-time reverse-transcriptase polymerase chain reaction (RT-PCR). The performance for detecting diseases was statistically analysed. The expression of miRNAs was further validated in the surgical tissues of enrolled patients. Four miRNAs (miR-126-3p, -20b-5p, -451a, and -144-3p) were significantly up-regulated in SCC and AD compared with normal, and their expression levels correlated with disease severity and high-risk human papillomavirus infection. Receiver operating characteristic curve analyses revealed that the area under the curve values for miR-126-3p, -20b-5p, -451a, and -144-3p were 0.89, 0.90, 0.94, and 0.93, respectively, for SCC plus AD compared with normal, showing high accuracy of cancer detection. Real-time RT-PCR analyses confirmed the expression of these four miRNAs in frozen tissues from cervical cancer. miR-126-3p, -20b-5p, -451a, and -144-3p in cervical mucus are promising biomarkers for cervical cancer and high-grade CINs.

Citing Articles

MicroRNA-Based Liquid Biopsy for Cervical Cancer Diagnostics and Treatment Monitoring.

Kepsha M, Timofeeva A, Chernyshev V, Silachev D, Mezhevitinova E, Sukhikh G Int J Mol Sci. 2025; 25(24.

PMID: 39769036 PMC: 11678179. DOI: 10.3390/ijms252413271.

Analysis of precancerous lesion-related microRNAs for early diagnosis of cervical cancer in the Thai population.

Suvanasuthi R, Therasakvichya S, Kanchanapiboon P, Promptmas C, Chimnaronk S Sci Rep. 2025; 15(1):142.

PMID: 39747449 PMC: 11696073. DOI: 10.1038/s41598-024-84080-1.

Identification of proteins' expression pathway and the effective miRNAs for the treatment of human papillomavirus-induced cervical cancer: in-silico analyses-experimental research.

Monemi M, Garrosi L, Mirzaei S, Farhadi B, Disfani R, Zabihi M Ann Med Surg (Lond). 2024; 86(10):5784-5792.

PMID: 39359748 PMC: 11444621. DOI: 10.1097/MS9.0000000000002513.

An Observation of the Microstructure of Cervical Mucus in Cows during the Proestrus, Estrus, and Metestrus Stages and the Impact on Sperm Penetration Ability.

Huang F, Zhang L, Niu P, Li X, Wang X, Wang J Vet Sci. 2024; 11(9).

PMID: 39330770 PMC: 11435960. DOI: 10.3390/vetsci11090391.

Analysis of miR-497/195 cluster identifies new therapeutic targets in cervical cancer.

Karunakara S, Eswaran S, Mallya S, Suresh P, Chakrabarty S, Kabekkodu S BMC Res Notes. 2024; 17(1):217.

PMID: 39095857 PMC: 11297691. DOI: 10.1186/s13104-024-06876-8.

References

Zhang Y, Zhang D, Wang F, Xu D, Guo Y, Cui W . Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer. Sci Rep. 2015; 5:17942. PMC: 4677300. DOI: 10.1038/srep17942. View

. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 2014; 125(2):97-8. DOI: 10.1016/j.ijgo.2014.02.003. View

Cheung T, Man K, Yu M, Yim S, Siu N, Lo K . Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle. 2012; 11(15):2876-84. DOI: 10.4161/cc.21278. View

Hui A, Lin A, Xu W, Waldron L, Perez-Ordonez B, Weinreb I . Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin Cancer Res. 2013; 19(8):2154-62. DOI: 10.1158/1078-0432.CCR-12-3572. View

Wang X, Tang S, Le S, Lu R, Rader J, Meyers C . Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 2008; 3(7):e2557. PMC: 2438475. DOI: 10.1371/journal.pone.0002557. View

Sirker M, Fimmers R, Schneider P, Gomes I . Evaluating the forensic application of 19 target microRNAs as biomarkers in body fluid and tissue identification. Forensic Sci Int Genet. 2016; 27:41-49. DOI: 10.1016/j.fsigen.2016.11.012. View

Juan L, Tong H, Zhang P, Guo G, Wang Z, Wen X . Identification and characterization of novel serum microRNA candidates from deep sequencing in cervical cancer patients. Sci Rep. 2014; 4:6277. PMC: 4152751. DOI: 10.1038/srep06277. View

Fischer J, Bachmann L, Jaeschke R . A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003; 29(7):1043-51. DOI: 10.1007/s00134-003-1761-8. View

Moriarty A, Wilbur D . Those gland problems in cervical cytology: faith or fact? Observations from the Bethesda 2001 terminology conference. Diagn Cytopathol. 2003; 28(4):171-4. DOI: 10.1002/dc.10278. View

10.

Sudo H, Mizoguchi A, Kawauchi J, Akiyama H, Takizawa S . Use of non-amplified RNA samples for microarray analysis of gene expression. PLoS One. 2012; 7(2):e31397. PMC: 3280296. DOI: 10.1371/journal.pone.0031397. View

11.

Azuma Y, Kusumoto-Matsuo R, Takeuchi F, Uenoyama A, Kondo K, Tsunoda H . Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. Jpn J Clin Oncol. 2014; 44(10):910-7. DOI: 10.1093/jjco/hyu112. View

12.

Sapre N, Macintyre G, Clarkson M, Naeem H, Cmero M, Kowalczyk A . A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. Br J Cancer. 2016; 114(4):454-62. PMC: 4815774. DOI: 10.1038/bjc.2015.472. View

13.

Liu D, Liu C, Wang X, Ingvarsson S, Chen H . MicroRNA-451 suppresses tumor cell growth by down-regulating IL6R gene expression. Cancer Epidemiol. 2014; 38(1):85-92. DOI: 10.1016/j.canep.2013.12.005. View

14.

Sureban S, May R, Weygant N, Qu D, Chandrakesan P, Bannerman-Menson E . XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Lett. 2014; 351(1):151-61. DOI: 10.1016/j.canlet.2014.05.011. View

15.

Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

16.

Sierzega M, Kaczor M, Kolodziejczyk P, Kulig J, Sanak M, Richter P . Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331. Br J Cancer. 2017; 117(2):266-273. PMC: 5520523. DOI: 10.1038/bjc.2017.190. View

17.

Yu Q, Liu S, Wang H, Shi G, Yang P, Chen X . miR-126 Suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin. Asian Pac J Cancer Prev. 2014; 14(11):6569-72. DOI: 10.7314/apjcp.2013.14.11.6569. View

18.

Hong S, Yu S, Li J, Yin Y, Liu Y, Zhang Q . MiR-20b Displays Tumor-Suppressor Functions in Papillary Thyroid Carcinoma by Regulating the MAPK/ERK Signaling Pathway. Thyroid. 2016; 26(12):1733-1743. DOI: 10.1089/thy.2015.0578. View

19.

Harden M, Prasad N, Griffiths A, Munger K . Modulation of microRNA-mRNA Target Pairs by Human Papillomavirus 16 Oncoproteins. mBio. 2017; 8(1). PMC: 5210503. DOI: 10.1128/mBio.02170-16. View

20.

Granados Lopez A, Lopez J . Multistep model of cervical cancer: participation of miRNAs and coding genes. Int J Mol Sci. 2014; 15(9):15700-33. PMC: 4200848. DOI: 10.3390/ijms150915700. View